A new study report in Science suggests SARS-CoV-2 and its mutated new variants can evade immune responses via the selective deletion of small sections of the virus’s genetic sequence.

Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.

A Biogen corporate meeting held in Boston in March that was initially connected to about 100 cases of COVID-19 could have led to a significantly higher number of infections.

Switzerland’s Roche acquired genetic sequencing company Stratos Genomics for an undisclosed amount.

In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.

Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug.